Members Across 16 States Implement a Management Services Organization to Further Its Mission to Improve Cancer Care Outcomes.
Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
QCCA Welcomes Stockton Hematology Oncology Medical Group!
Stockton Hematology Oncology was established in 1991 to provide comprehensive care for patients diagnosed with cancer and blood disorders.
With 4 locations in San Joaquin County, we offer a full spectrum of cancer care that focuses on prevention, screening, diagnosis and treatment of all cancers and blood diseases.
We are very excited to have Stockton Hematology Oncology join QCCA!
QCCA Welcomes Essex Oncology of North Jersey to its member practices!
Essex Oncology is a select group of cancer specialists with a common vision: to provide world-class cancer treatment with an unsurpassed level of compassion and personal attention. Unlike larger oncology group practices, the Essex team applies their world-class training and expertise in a smaller, more intimate and personal treatment setting. As a result, patients receive the most innovative cancer treatments available in an environment that is comfortable and encouraging at every stage—from diagnosis through treatment and beyond.
We are excited to add the expertise from Essex Oncology to our amazing group of practices within QCCA!
QCCA Evolves to Become the First National Clinically Integrated Network in Oncology
Through the CIN model, QCCA’s network will further support its practice members through a robust health information exchange, care coordination and management services, and contracting support that will allow for the development of better methods for delivering improved outcomes in all aspects of cancer care delivery.
Take a moment to read this interesting article detailing the journey or Dr. Tony Blau and Dr. Sibel Blau during Tony’s battle with multiple myeloma.
Liu J, Halloran JT, Bilmes JA, Daza RM, Lee C, Mahen EM, Prunkard D, Song C, Blau S, Dorschner MO, Gadi VK, Shendure J, Blau CA, Noble WS.
Sci Rep. 2017 Dec 5;7(1):16943. doi: 10.1038/s41598-017-16813-4.
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, O’Regan R, Mouret-Reynier MA, Kalev D, Egle D, Csőszi T, Bordonaro R, Decker T, Tjan-Heijnen VCG, Blau S, Schirone A, Weber D, El-Hashimy M, Dharan B, Sellami D, Bachelot T.
Lancet Oncol. 2018 Jan;19(1):87-100. doi: 10.1016/S1470-2045(17)30688-5. Epub 2017 Dec 7.
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators.
Lancet Oncol. 2017 Oct;18(10):1360-1372. doi: 10.1016/S1470-2045(17)30450-3. Epub 2017 Aug 8.
Sawas A, Farber CM, Schreeder MT, Khalil MY, Mahadevan D, Deng C, Amengual JE, Nikolinakos PG, Kolesar JM, Kuhn JG, Sportelli P, Miskin HP, O’Connor OA.
Br J Haematol. 2017 Apr;177(2):243-253. doi: 10.1111/bjh.14534. Epub 2017 Feb 21.